Literature DB >> 32323879

Adjuvant chemotherapy for patients with gastric neuroendocrine carcinomas or mixed adenoneuroendocrine carcinomas.

J-P Lin1,2, Y-J Zhao3, Q-L He4, H-K Hao5, Y-T Tian6, B-B Zou7, L-X Jiang8, W Lin9, Y B Zhou10, Z Li11, Y-C Xu12, G Zhao13, F-Q Xue14, S-L Li15, W-H Fu16, Y-X Li7, X-J Zhou17, Y Li18, Z-G Zhu19, J-P Chen20, Z-K Xu21, L-H Cai22, E Li23, H-L Li24, J-W Xie1,2, C-M Huang1,2, P Li1,2, J-X Lin1,2, C-H Zheng1,2.   

Abstract

BACKGROUND: The aim of this study was to evaluate whether adjuvant chemotherapy is associated with improved survival in patients with resectable gastric neuroendocrine carcinomas (G-NECs) or mixed adenoneuroendocrine carcinomas (G-MANECs).
METHODS: The study included patients with G-NECs or G-MANECs who underwent surgery in one of 21 centres in China between 2004 and 2016. Propensity score matching analysis was used to reduce selection bias, and overall survival (OS) in different treatment groups was estimated by the Kaplan-Meier method.
RESULTS: In total, 804 patients with resectable G-NECs or G-MANECs were included, of whom 490 (60·9 per cent) received adjuvant chemotherapy. After propensity score matching, OS in the chemotherapy group was similar to that in the no-chemotherapy group. Among patients with G-NECs, survival in the fluorouracil (5-FU)-based chemotherapy group and the non-5-FU-based chemotherapy group was similar to that in the no-chemotherapy group. Similarly, etoposide plus cisplatin or irinotecan plus cisplatin was not associated with better OS in patients with G-NECs. Among patients with G-MANECs, OS in the non-5-FU-based chemotherapy group was worse than that in the no-chemotherapy group. Patients with G-MANECs did not have better OS when platinum-based chemotherapy was used.
CONCLUSION: There was no survival benefit in patients who received adjuvant chemotherapy for G-NECs or G-MANECs.
© 2020 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Year:  2020        PMID: 32323879     DOI: 10.1002/bjs.11608

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  4 in total

1.  Therapeutic strategies for gastroenteropancreatic neuroendocrine neoplasms: State-of-the-art and future perspectives.

Authors:  Elettra Merola; Andrea Michielan; Umberto Rozzanigo; Marco Erini; Sandro Sferrazza; Stefano Marcucci; Chiara Sartori; Chiara Trentin; Giovanni de Pretis; Franca Chierichetti
Journal:  World J Gastrointest Surg       Date:  2022-02-27

2.  Conditional cause-specific survival after chemotherapy and local treatment for primary stage IV breast cancer: A population-based study.

Authors:  Min Xiao; Pin Zhang
Journal:  Front Oncol       Date:  2022-08-05       Impact factor: 5.738

3.  Mixed large and small cell neuroendocrine carcinoma of the stomach: A case report and review of literature.

Authors:  Ze-Feng Li; Hai-Zhen Lu; Ying-Tai Chen; Xiao-Feng Bai; Tong-Bo Wang; He Fei; Dong-Bing Zhao
Journal:  World J Clin Cases       Date:  2022-06-06       Impact factor: 1.534

4.  Gastric Mixed Neuroendocrine Non-Neuroendocrine Neoplasms: A Western Center Case Series.

Authors:  Marcus Fernando Kodama Pertille Ramos; Marina Alessandra Pereira; Arthur Youssif Mota Arabi; Melissa Mello Mazepa; Andre Roncon Dias; Ulysses Ribeiro; Bruno Zilberstein; Sergio Carlos Nahas
Journal:  Med Sci (Basel)       Date:  2021-06-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.